Exactech, Inc. (EXAC) Director James G. Binch Sells 747 Shares

Exactech, Inc. (NASDAQ:EXAC) Director James G. Binch sold 747 shares of the stock in a transaction on Friday, August 4th. The stock was sold at an average price of $28.40, for a total transaction of $21,214.80. Following the transaction, the director now directly owns 3,554 shares in the company, valued at $100,933.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Exactech, Inc. (NASDAQ:EXAC) opened at 29.95 on Friday. The stock has a 50 day moving average of $29.41 and a 200 day moving average of $28.11. The stock has a market cap of $429.72 million, a P/E ratio of 575.96 and a beta of 1.02. Exactech, Inc. has a one year low of $22.20 and a one year high of $31.90.

Exactech (NASDAQ:EXAC) last announced its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.33. The company had revenue of $67.30 million for the quarter, compared to analysts’ expectations of $67.75 million. Exactech had a net margin of 0.30% and a return on equity of 7.39%. Exactech’s revenue was up 1.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.31 EPS. On average, analysts forecast that Exactech, Inc. will post $1.29 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “[[title]]” was published by [[site]] and is owned by of [[site]]. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at [[permalink]].

Several brokerages have recently commented on EXAC. BidaskClub upgraded shares of Exactech from a “sell” rating to a “hold” rating in a report on Friday. Gabelli reiterated a “buy” rating on shares of Exactech in a report on Monday, July 31st. TheStreet upgraded shares of Exactech from a “c+” rating to a “b” rating in a report on Tuesday, April 25th. Finally, Zacks Investment Research upgraded shares of Exactech from a “sell” rating to a “hold” rating in a report on Tuesday, April 25th.

A number of institutional investors have recently bought and sold shares of EXAC. Bank of Montreal Can bought a new position in Exactech during the second quarter valued at about $134,000. Salem Investment Counselors Inc. bought a new position in Exactech during the first quarter valued at about $129,000. American International Group Inc. boosted its position in Exactech by 7.1% in the first quarter. American International Group Inc. now owns 6,423 shares of the medical equipment provider’s stock valued at $162,000 after buying an additional 424 shares in the last quarter. Hancock Holding Co. bought a new position in Exactech during the second quarter valued at about $212,000. Finally, JPMorgan Chase & Co. boosted its position in Exactech by 2,693.8% in the first quarter. JPMorgan Chase & Co. now owns 7,627 shares of the medical equipment provider’s stock valued at $192,000 after buying an additional 7,354 shares in the last quarter. Institutional investors and hedge funds own 64.05% of the company’s stock.

Exactech Company Profile

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.